Bao Feng made a breakthrough in the application of nervonic acid molecules for Parkinson's disease screening, together with Xuanwu Hospital.

• Date：2022-06-28

• By：Zhong Yuan Biotech

Bao Feng’s, a subsidiary of Zhong Yuan, R&D team together with the group of Xuanwu Hospital, Dr. Chaodong Wang, has made a breakthrough in the field of Parkinson's disease. The relevant research results of Bao Feng's biological research team have applied for invention patents and obtained intellectual property protection.

Among more than 5 million Parkinson's patients worldwide, there are nearly 3 million in China. The incidence of Parkinson's disease may be as high as 260 per 1 million people, with the incidence rate at age 50 at about 0.5%, and up to 4% by age 80 or older, a full 10-fold increase. What's even more frightening is that Parkinson's disease has gradually shown a trend of rejuvenation in recent years, with adolescent Parkinson's clinically accounting for 10% of the total number of Parkinson's disease patients.

The clinical diagnosis of Parkinson's disease relies mainly on the patient's symptoms, especially motor symptoms, but characteristic manifestations such as resting tremor, myotonia, and bradykinesia can also be seen in other neurodegenerative diseases and interfere with the diagnosis of Parkinson's disease. CT and MRI examinations also generally do not have characteristic changes.

Electron emission tomography or single-photon emission computed tomography with specific radionuclide detection, which are expensive and require high operator requirements, have also not been widely used in clinical practice. This has resulted in a delayed treatment rate of up to 60% for early Parkinson's disease. The early screening and intervention of Parkinson's disease is the breakthrough of the research team of Bao Feng and the research group of the director of the Xuanwu Hospital, Dr. Chaodong Wang.

Studies have found that ceramide and sphingomyelin levels are lower in the brains of Parkinson's patients than in normal subjects, as evidenced by a significant decrease in very long chain ceramides (especially ceric acid) in the brain.

At the same time, we know that oxidative stress in the brain is one of the causes of neurodegenerative diseases, and it has been demonstrated that nervonic acid of plant origin has a neuroprotective effect, effectively inhibiting oxidative stress while strengthening the expression of antioxidant system in cells to achieve the protective effect of neural cells.

This time, the scientific research team of Bao Feng, together with Xuanwu Hospital, Dr. Chaodong Wang, made a breakthrough in the field of Parkinson's disease and obtained patents: "Biomarkers for diagnosis of Parkinson's disease and its application" Patent No. ZL2022100023332; "Combination of biomarkers for Parkinson's disease and its application Patent No. ZL2022100023258; "Biomarkers for Biomarkers for Parkinson's Disease Detection and Their Applications" Patent No. ZL2022100023277; "Biomarkers for Parkinson's Disease Diagnosis and Their Applications" Patent No. ZL2022100023328. These patents provide models for discriminating Parkinson's disease using a combination of ceramide type nervonic acid and other markers that can be used for early detection, diagnosis and prediction of Parkinson's disease in kit applications.

Xuanwu Hospital is a tertiary level A hospital with neuroscience as the key discipline, and its neurosurgery department is one of the earliest and largest neurology diagnosis, teaching and research centers in China. The cooperation between Bao Feng and Xuanwu Hospital, Dr. Chaodong Wang, hopes to provide practical help to millions of Parkinson's patients and potential patients in China, and believes that the early screening kit for Parkinson's disease will become an important weapon to overcome Parkinson's disease in the future, and Bao Feng will continue to forge ahead in the development of neuroscience!